The Vitreous Body and Its Role in the Diagnosis of Eye Pathologies

Main Article Content

Mónica Asencio-Duran José Vicente Dabad-Moreno Blanca Vicandi-Plaza Manzano Muñoz María Capote-Díez Gloria Amorena Santisteban


Vitreous humour is a biologically weak immune cavity of the eye, and is in some way isolated from pathogens of the rest of the organism due to a series of special immunological privileges. However, it is a place where processes of varied ethiology (immune, infectious or neoplastic) can develop indirectly due to leakage or release of molecules or even cells into the vitreous chamber, or may be the receptacle of molecules derived from processes developed in other organs in close contact with the vitreous (such as the retina or other underlying layers such as the choroid), which makes the vitreous body an accessible place for diagnosis and with less potential for side effects for analysis than other adjacent eye structures. This article reviews the most frequent pathologies that requires vitreous diagnosis, the most commonly used approaches for sampling and the diagnostic tests that can be performed on vitreous samples.

Keywords: masquerade syndrome, uveitis, lymphoma, vitritis, vitrectomy

Article Details

How to Cite
ASENCIO-DURAN, Mónica et al. The Vitreous Body and Its Role in the Diagnosis of Eye Pathologies. Medical Research Archives, [S.l.], v. 9, n. 9, sep. 2021. ISSN 2375-1924. Available at: <>. Date accessed: 22 feb. 2024. doi:
Review Articles


1. Szirmai JA, Balazs EA. Studies on the Structure of the Vitreous Body: III. Cells in the Cortical Layer. AMA Arch Ophthalmol 1958;59(1):34-48.
2. Burke JM, Sipos E, Cross HE. Cell proliferation in response to vitreous hemoglobin. Invest Ophthalmol Vis Sci 1981;20(5):575-581.
3. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34(12):3347-54.
4. Yoshitoshi T, Shichi H. Immunosuppressive factors in porcine vitreous body. Curr Eye Res 1991;10(12):1141-9.
5. Mendoza PR, Grossniklaus HE. Updates in ophthalmic pathology. Indian J Ophthalmol. 2017; 65(5): 347-353.
6. Bloch‐Michel E, Nussenblatt RB. International uveitis study recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987; 103:234-235.
7. Rothova A, et al. Uveitis masquerade syndromes. Ophthalmology 2001; 108:386-399.
8. Whitcup SM, Nussenblatt RB. Immunologic mechanisms of uveitis. Arch Ophthalmol 1997; 115:520-525.
9. Dick AD. Immune mechanisms of uveitis: Insights into disease pathogenesis and treatment. Int Ophthalmol Clin 2000; 40:1-18.
10. Hausmann S, Wucherpfennig KW. Activation of autoreactive T cells by peptides from human pathogens. Curr Opin Immunol 1996;9:831-838.
11. Sugi‐Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin‐2 and interferon‐gamma‐producing T cells in patients with active Behçet’s disease. Invest Ophthalmol Vis Sci 1998; 39:996-1004.
12. Chana CC, Rubensteinb JL, Coupland SE, et al. Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium. Oncologist 2011;16(11):1589-1599.
13. Char DJ, Ljung BM, Miller T, Phillips T. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 1988;95:625-30.
14. Rockwood EJ, Zakov ZN, Bay JW. Combined malignant lymphoma of the eye and CNS (reticulum-cell sarcoma). Report of three cases. J Neurosurg 1984;61:369-74.
15. Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 1993;100:1399-406.
16. Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist’s role. Eye 2004; 18:663-672.
17. Swartz M, Schumann GB. Acute leukaemic infiltration of the vitreous diagnosed by pars plana aspiration. Am J Ophthalmol 1980;90:326-330.
18. Zhioua R, Boussen I, Malek I, et al. Acute lymphoblastic leukaemia and vitreous infiltration. A case study. J Français Ophthalmol 2001;24:180-182.
19. Chinnam M, Goodrich DW. RB1, development and cancer. Curr Top Dev Biol. 2011; 94: 129–169.
20. Singh HM, Thomas VM, Lia NL, Madgula AS, Putra I, Vredenburgh J. Lung adenocarcinoma with metastasis to the vitreous – A case report and review of literature, Current Problems in Cancer: Case Reports, Volume 3, 2021, 100064, ISSN 2666-6219,
21. Gelman R, Lee SE, Rocha N, Kayserman LG, Vallar RV, Marr BP. Vitreous Metastasis in a Case of Metastatic Breast Cancer. Ocul Oncol Pathol 2020;6(5):323-327.
22. Praidou A, Jacob S, Irion L, Sivaraj R, Groenewald C, Coupland SE, Heimann H. BMC Cancer 2017; 17: 430.
23. Manusow, JS, Khoja, L, Pesin N. et al. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunotherapy Cancer 2014; 2, 41.
24. Kim CY, Ha CW, Lee SC. Vitreous and Retinal Metastasis from Gastric Cancer. Eur J Ophthalmol 2010;20(3):615-617.
25. Parija, J. Vitreous Humor Metastasis in Squamous Cell Carcinoma of Cervix. Indian J Gynecol Oncolog 2017; 15, 31.
26. Yang RH, Lee TH, Chu YK. A rare metastasis to the vitreous from primary breast lymphoma Oncol Clin Pract 2016; 12, 3: 108-111
27. Biswas J, Annamalai R, Krishnaraj V. Biopsy Pathology in Uveitis. Middle East Afr J Ophthalmol 2011;18(4):261-267.
28. Allegonda Van der Lelij, Aniki Rothovab. Diagnostic anterior chamber paracentesis in uveitis: a safe procedure? Br J Ophthalmol 1997;81:976-979.
29. Finger PT, Papp C, Latkany P, et al. Anterior chamber paracentesis cytology (cytospin technique) for the diagnosis of intraocular lymphoma. Br J Ophthalmol 2006;90:690-692.
30. Augsburger JJ. Invasive diagnostic techniques for uveitis and simulating conditions. Trans Am Ophthalmol Soc 1990;88:89-104.
31. Sarafzadeh S, Corrêa ZM, Dhamija A, et al. Intraocular lymphoma diagnosed by fine-needle aspiration biopsy. Acta Ophthalmol 2010:88:705-710.
32. Donahue SP, Kowalski RP, Jewart BH, et al. Vitreous cultures in suspected endophthalmitis. Biopsy or vitrectomy? Ophthalmology 1993;100:452-5.
33. Okhravi N, Towler HMA, Hykin P, et al. Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis. Br J Ophthalmol 1997;81:719-25.
34. Lobo A, Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. Ophthalmology 2003;110:595-599.
35. Eide N, Walaas L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. Acta Ophthalmol 2009;87(6):588-601.
36. Donahue SP, Kowalski RP, Jewart BH, et al. Vitreous cultures in suspected endophthalmitis. Biopsy or vitrectomy? Ophthalmology 1993;100:452-5.
37. Li KK, Chan WM, Tam BS, et al. Needle tap in the diagnosis of inflammation. Ophthalmology 2004;111(3):609; author reply 609-10.
38. Asencio-Duran M, Vallejo-Garcia JL, Pastora-Salvador N, Fonseca-Sandomingo A, Romano MR. Vitreous diagnosis in neoplastic diseases. Mediators Inflamm. 2012;2012:930704. doi:10.1155/2012/930704
39. Quiroz-Mercado H, Rivera-Sempertegui J, Macky TA, et al. Performing vitreous biopsy by perfluorocarbon-perfused vitrectomy. Am J Ophthalmol 2005;140:1161-1163.
40. Patel DS, Khan IJ, Zayed MG, Partridge D, Rennie IG, Mudhar HS, Sheard R. Full diagnostic vitrectomy with posterior vitreous detachment induction for the diagnosis of vitritis due to uncertain etiology. Retina 2019;39(10):1872-1879.
41. Zaldivar RA, Martin DF, Holden JT, et al. Primary Intraocular Lymphoma. Clinical, cytologic, and flow cytometric analysis. Ophthalmology 2004;111: 1762-1767.
42. Palexas GN, Green WR, Goldberg MF, Ding Y. Diagnostic pars plana vitrectomy report of a 21-year retrospective study. Trans Am Ophthalmol Soc 1995;93: 281-308.
43. Liu K, Klintworth GK, Dodd LG. Cytologic findings in vitreous fluids: analysis of 74 specimens. Acta Cytol 1999; 43:201-206.
44. Coupland SE, Bechrakis NE, Anastassiou G, et al. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome. Graefes Arch Clin Exp Ophthalmol 2003; 241:860-870.
45. Mruthyunjaya P, Jumper M, McCallum R. Diagnostic yield of vitrectomy in eyes with suspected posterior segment infection or malignancy. Ophthalmology 2002;109:1123-1129.
46. Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol 2005; 140:822-829.
47. Johnston RL, Tufail A, Lightman S, et al. Retinal and choroidal biopsies are helpful in unclear uveitis of suspected infectious or malignant origin. Ophthalmology 2004;111:522–528.
48. Shields CL, Materin MA, Teixeira L, et al. Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. Ophthalmology 2007; 114: 1919-1924.
49. McCannel TA, Chang MY, Burgess BL. Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology 2012;119:606-10.
50. Harbour JW. Molecular prognostic testing in uveal melanoma: has it finally come of age? Arch Ophthalmol 2007;125:1122-1123.
51. Overgaard J. Uveal malignant melanoma. An ophthalmological or oncological disease? Acta Ophthalmol Scand 1996; 74: 313.
52. Westerfeld C, Mukai S. Retinal and choroidal biopsy. Int Ophthalmol Clin 2009;49:145-54.
53. Pelayes DE, Zárate JO, Biscotti CV, Singh AD. Calibrated needle for ophthalmic fine needle aspiration biopsy. Br J Ophthalmol 2012;96(8):1147-8.
54. Jakobiec FA, Coleman DJ, Chattock A, Smith M. Ultrasonically guided needle biopsy and cytologic diagnosis of solid intraocular tumors. Ophthalmology 1979;86:1662-1678.
55. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol 2016;100(4):456-62.
56. Cohen VM, Dinakaran S, Parsons MA, Rennie IG. Transvitreal fine-needle aspiration biopsy: the influence of intraocular lesion size on diagnostic biopsy result. Eye 2001;15:143-147.
57. Augsburger JJ, Correa ZM, Schneider S, et al. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc 2002; 100:225-232.
58. Kivela T, Simpson E.R, Grossniklaus H.E, Jager M.J, Sough A.D, Caminal J.M. Uveal melanoma. In AJCC Cancer Staging Manual, 8th ed.; Amin EB, Edge S, Greene F, Byrd DR., Brookland KR, Washington, M.K., Eds.; Springer: New York, NY, USA; pp. 805–817
59. Kashyap S, Sethi S, Meel R, Pushker N, Sen S, Bajaj MS, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med 2012;136(2):190-193.
60. Chong EM, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chévez-Barrios P. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med 2006;130(11):1669-72.
61. Amemiya T, Yoshida H, Ishigooka H. Vitreous seeds in retinoblastoma, clinical significance and ultrastructure. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1979;211(3):205–13.
62. Berry JL, Xu L, Murphree AL, et al. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. JAMA Ophthalmol 2017;135(11):1221-1230.
63. Shen DF, Zhuang Z, LeHoang P, et al. Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. Ophthalmology 1998;105:1664-1669.
64. Whitcup SM, Chan CC, Buggage RR, et al. Improving the diagnostic yield of vitrectomy for intraocular lymphoma. Arch Ophthalmol 2000; 118:446.
65. Davis JL, Solomon D, Nussenblatt RB, et al. Immunocytochemical staining of vitreous cells. Indications, techniques, and results. Ophthalmology 1992; 99:250-256.
66. Davis, J. Intraocular lymphoma: a clinical perspective. Eye 2013; 27:153-162.
67. Iwamoto S, Burrows RC, Kalina RE, George D, Boehm M, Bothwell M, et al. Immunophenotypic differences between uveal and cutaneous melanomas. Arch Ophthalmol 2002, 120, 466-470.
68. Sakuma T, Iseki R, Mimura A Rapid cytologic diagnosis of choroidal malignant melanoma by vitreous smear. J Fr Ophtalmol 2012 Jun 1 [Epub ahead of print]
69. Spraul CW, Martin DF, Hagler WS. Cytology of metastatic cutaneous melanoma to the vitreous and retina. Retina 1996;16(4):328-32.
70. Missotten T, Tielemans D, Bromberg JE, van Hagen PM, van Lochem EG, van Dongen JJ, et al. Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma. Ophthalmology 2013;120, 991-996.
71. Tan WJ, Wang MM, Ricciardi-Castagnoli P, Chan ASY, Lim TS. Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses. Front Mol Biosci 2021;11;7:611017.
72. Mochizuki M, Sugita S, Kamoi K, et al. A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases. Jpn J Ophthalmol 2017;61: 1-20.
73. Rothova A, de Boer JH, Ten Dam-van Loon NH, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology 2008;115:306-311.
74. Yokota M, Takase H, Imai Y, et al. One case of intraocular malignant lymphoma diagnosed by immunoglobulin gene rearrangement and translocation, and IL-10/IL-6 ratio in the vitreous fluid. Nippon Ganka Gakkai Zasshi 2003;107:287-291.
75. Wang Y, Shen D, Wang VM, et al. Molecular Biomarkers for the Diagnosis of Primary Vitreoretinal Lymphoma. Int J Mol Sci 2011, 12, 5684-5697.
76. Benjamin D, Park CD, Sharma V. Human B cell interleukin 10. Leuk Lymphoma 1994;12:205-210.
77. Baehring JM, Androudi S, Longtine JJ, et al. Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer 2005; 104:591-597.
78. Wang Y, Shen D, Wang VM, Sen HN, Chan CC. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma. Int J Mol Sci 2011; 12(9):5684-97.
79. Zhang Y, Wang H, Ren C, Yu H, Fang W, Zhang N, et al. Correlation between C-MYC, BCL-2, and BCL-6 protein expression and gene translocation as biomarkers in diagnosis and prognosis of diffuse large B-cell lymphoma. Front Pharmacol 2018; 9:1497. 10.3389/fphar.2018.01497.
80. Kase S, Namba K, Iwata D, Mizuuchi K, Kitaichi N, Tagawa Y, et al. Diagnostic efficacy of cell block method for vitreoretinal lymphoma. Diagn Pathol 2016; 11, 29. 10.1186/s13000-016-0479-1.
81. Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma. Oncotarget 2014;5(13):5065-5075.
82. Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, Nierkens S, Ossewaarde-van Norel J, de Boer JH, et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction. JAMA Ophthalmol 2018;136(10):1098-1104.
83. Minezaki T, Usui Y, Asakage M, et al. High-Throughput MicroRNA Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis. J Clin Med 2020;9(6):1844.
84. Perez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: The Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 2004; 12:193-201.
85. El‐Shabrawi Y, Livir‐Rallatos C, Christen W, et al. High levels of interleukin‐12 in the aqueous and vitreous of patients with uveitis. Ophthalmology 1998; 105:1659-1663.
86. Davis, J. Intraocular lymphoma: a clinical perspective. Eye 2013; 27:153-162.
87. Kimura K, Usui Y, Goto H, Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 2012; 56(4):383-9.
88. Akpek EK, Maca SM, Christen WG, et al. Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma. Ophthalmology 1999;106:2291-2295.
89. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9.
90. Vaarwater J, van den Bosch T, Mensink HW, van Kempen C, Verdijk RM, Naus NC, Paridaens D, Brüggenwirth HT, Kiliç E, de Klein A. Multiplex ligation-dependent probe amplification equals fluorescence in-situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma. Melanoma Res 2012;22(1):30-7.
91. Mudhar HS, Doherty RE, Salvi SM, Currie ZI, Tan JH, Sisley K. Genetic Profiling of Primary Orbital Melanoma: An Analysis of 6 Cases with Clinicopathologic Correlation. Ophthalmology 2019;126(7):1045-1052.
92. Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 2014;27(10):1321-30.
93. Harbour JW, Chen R. The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. PLoS Curr. 2013 Apr 9;5:ecurrents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618.doi: 10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618.
94. Hughes S, Damato BE, Giddings I, Hiscott PS, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer 2005;93:1191–1196.
95. Venkatesan N, Kanwar J, Deepa PR, Khetan V, Crowley TM, Raguraman R, et al. Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations. PLoS One. 2016 Jan 26;11(1):e0146128. doi: 10.1371/journal.pone.0146128.
96. Lee WW, Bookstein R, Hong F, Young LJ, Shew JY, Lee HY. Human retinoblastoma susceptibility gene: Cloning, identification and sequence. Science 1987; 235: 1394-9.
97. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220–5227.
98. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 2010; 13(16):1292-303.
99. Kooi IE, Mol BM, Massink MP, et al. A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression. PLoS One. 2016;11(4):e0153323. Published 2016 Apr 26. doi:10.1371/journal.pone.0153323
100. Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M, Peet C, McConville CM. Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer 2013; 23; 109(2): 512–525.
101. Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and Molecular Diagnostics in Retinoblastoma--An Update. Asia Pac J Ophthalmol (Phila) 2017;6(2):197-207.
102. Goto H, Usui M, Wakamatsu K, Ito S. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma. Jpn J Ophthalmol 2001;45(5):538-42.
103. Cochran AJ, Holland GN, Saxton RE, et al. Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma. Br J Ophthalmol 1988;72(11):874–879.
104. Velez J, Nguyen G, Chemudupati HV, et al. Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. Mol Cancer 20, 39 (2021).
105. Berry JL, Xu L, Murphree AL, Krishnan S, Stachelek K, Zolfaghari E, et al. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. JAMA Ophthalmol 2017; 1;135(11):1221-1230.
106. Margolis R, Brasil OF, Lowder CY, et al. Vitrectomy for the diagnosis and management of uveitis of unknown cause. Ophthalmology 2007; 114:1893-1897.
107. Johnston RL, Tufail A, Lightman S, et al. Retinal and choroidal biopsies are helpful in unclear uveitis of suspected infectious or malignant origin. Ophthalmology 2004; 111:522-528.